MedPath

Mutation p.Ile112Thr : Discrepancy Between Factor IX Level and Bleeding Phenotype

Conditions
Hemophilia B
Interventions
Other: data collection
Registration Number
NCT03946384
Lead Sponsor
Centre Hospitalier Universitaire Dijon
Brief Summary

It appears that the mutation p.Ile112Thr in the factor IX gene confers a discrepancy between mild factor IX level and severe bleeding phenotype. Databases and litterature analysis are poor on this matter. The goal of this study is to compile bleeding phenotype in patients with this specific mutation to prove the clinico-biological discordance in order to improve patient care and follow-up.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
12
Inclusion Criteria
  • hemophilia B with p.Ile112Thr mutation on factor IX gene
Exclusion Criteria

None

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
patientsdata collectionHemophilia B with p.Ile112Thr mutation on factor IX gene
Primary Outcome Measures
NameTimeMethod
Bleeding phenotypeThrough study completion, an average of 4 months

bleeding phenotype in patients with p.Ile112Thr in factor IX gene

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

CHU Dijon Bourgogne

🇫🇷

Dijon, France

© Copyright 2025. All Rights Reserved by MedPath